Clinical Report: The Benefits of Single Fraction Stereotactic Body Radiation Therapy (SBRT)

Overview

Recent findings indicate that a single fraction of SBRT is as effective as multiple fractions for treating peripherally located lung cancer. This approach not only reduces treatment costs but also enhances patient convenience, particularly during the pandemic.

Background

Stereotactic body radiation therapy (SBRT) has emerged as a critical treatment option for early-stage lung cancer, especially for patients who are medically inoperable. The ability to deliver effective radiation in a single session can significantly improve patient outcomes by minimizing treatment burden and costs. Current guidelines advocate for the adoption of single-fraction SBRT, emphasizing its potential to streamline cancer care.

Data Highlights

No numerical data available.

Key Findings

• Single-fraction SBRT is as effective as three, four, or five fractions for peripheral lung cancer.
• One fraction of SBRT costs approximately one-third of the price of three fractions.
• Patients experience reduced overall radiation exposure with single-fraction treatment.
• International guidelines support the broader adoption of single-fraction SBRT for lung cancer.
• Clinical trials have shown no significant difference in outcomes between one and multiple fractions.

Clinical Implications

Healthcare providers should consider implementing single-fraction SBRT as a standard treatment for patients with peripheral lung cancer to enhance convenience and reduce costs. This approach aligns with current clinical guidelines and may improve patient adherence to treatment plans.

Conclusion

The findings support the transition towards single-fraction SBRT as a preferred treatment modality for lung cancer, promising both efficacy and improved patient experience. Continued research may further validate its application in other cancer types.

References

1. The ASCO Post, 2014 -- Stereotactic Body Radiation Therapy an Effective Option for Early-Stage Lung Cancer Patients
2. Journal of Neuro-Oncology, 2014 -- Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors
3. The ASCO, 2018 -- ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
4. ASTRO guideline, 2017 -- SBRT in early NCSLC - American Society for Radiation Oncology (ASTRO)
5. PubMed, 2015 -- A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)
6. The ASCO Post — SBRT vs Conventionally Fractionated, or Moderately Hypofractionated External-Beam Radiotherapy, for Localized Prostate Cancer
7. ASTRO guideline - SBRT in early NCSLC - American Society for Radiation Oncology (ASTRO)
8. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927) - PubMed
9. Comparison of Survival Outcomes of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Early-Stage Central or Peripheral NSCLC - PMC